At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,444 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Insulin Degludec for Type 2 Diabetes Mellitus. Completed, enrolled 1,444 participants across 122 sites in 13 countries.
Detailed Summary
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesArgentina, Austria, Greece, Hungary, Italy, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMar 2019
Enrollment StartApr 2019
Primary CompletionDec 2020
Study CompletionJan 2021
TodayJul 2026
First PostedMar 20, 2019
Enrollment StartApr 1, 2019
Primary CompletionDec 11, 2020
Study CompletionJan 4, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.3 years ago
Interventions
Tirzepatidedrug
Administered SC
Insulin Degludecdrug
Administered SC